Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU)
arcticnovartis
Fri, 02/27/2026 – 12:34
Read more about Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU)
…
Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU)
arcticnovartis
Fri, 02/27/2026 – 12:34
Read more about Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU)
…
Novartis to build new radioligand therapy site in Denton, Texas, delivering more next‑generation treatments to patients
arcticnovartis
Wed, 02/25/2026 – 13:04
Read more about Novartis to build new radioligand therapy site in Denton, Texas, deliver…
New real‑world data reinforce earlier use of Pluvicto™ before chemotherapy in metastatic castration-resistant prostate cancer
arcticnovartis
Tue, 02/24/2026 – 13:19
Read more about New real‑world data reinforce earlier use of Pluvicto™ before chem…
New real‑world data reinforce earlier use of Pluvicto™ before chemotherapy in metastatic castration-resistant prostate cancer
arcticnovartis
Tue, 02/24/2026 – 13:19
Read more about New real‑world data reinforce earlier use of Pluvicto™ before chem…
Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)
arcticnovartis
Mon, 02/23/2026 – 19:49
Read more about Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potenti…
Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)
arcticnovartis
Mon, 02/23/2026 – 07:19
Read more about Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potenti…
Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)
arcticnovartis
Mon, 02/23/2026 – 07:19
Read more about Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potenti…
Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)
arcticnovartis
Wed, 02/18/2026 – 07:19
Read more about Novartis remibrutinib first therapy to achieve Phase III primary endpoint in ch…
Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)
arcticnovartis
Wed, 02/18/2026 – 07:19
Read more about Novartis remibrutinib first therapy to achieve Phase III primary endpoint in ch…
